LRRK2 and Parkinson disease: Taking PD as an example, studies have confirmed that LRRK2 inhibitors can improve dopaminergic neuron abnormalities in midbrain organoids harboring the LRRK2-G2019S mutation, demonstrating certain therapeutic potential (Pena et al., 2024).